PT - JOURNAL ARTICLE AU - ONDREJ FIALA AU - JAN BAXA AU - MARTIN SVATON AU - LUCIE BENESOVA AU - RENATA PTACKOVA AU - TEREZA HALKOVA AU - MAREK MINARIK AU - PETR HOSEK AU - MARCELA BURESOVA AU - JINDRICH FINEK AU - JIRI FERDA AU - MILOS PESEK TI - Combination of Circulating Tumour DNA and <sup>18</sup>F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study AID - 10.21873/cgp.20319 DP - 2022 Mar 01 TA - Cancer Genomics - Proteomics PG - 270--281 VI - 19 IP - 2 4099 - http://cgp.iiarjournals.org/content/19/2/270.short 4100 - http://cgp.iiarjournals.org/content/19/2/270.full SO - Cancer Genomics Proteomics2022 Mar 01; 19 AB - Background/Aim: Circulating tumour DNA (ctDNA) represents an emerging biomarker in non-small cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron emission tomography/computed tomography (PET/CT) in the follow-up monitoring of advanced-stage NSCLC patients treated with chemotherapy. Patients and Methods: Eighty-four patients were enrolled in this study. 18F-fluorodeoxyglucose PET/CT and ctDNA assessments were performed at baseline and after two cycles of chemotherapy (follow-up). Results: There was a correlation of ctDNA with metabolic tumour volume (MTV), total lesion glycolysis (TLG), and iodine concentration (IC) at baseline (p=0.001, p=0.001, p=0.003) and at follow-up (p=0.006, p=0.002, p=0.001). The objective response was associated with follow-up ctDNA (p&lt;0.001) and the change of all PET/CT parameters. ROC analyses showed that the combination of follow-up ctDNA with changes in SUVmax is very promising for the estimation of objective response and progression-free survival. Conclusion: The combination of ctDNA assessment with PET/CT is a promising approach for the follow-up monitoring of therapy response and prognosis estimation of advanced-stage NSCLC patients.